Russian Patient Gets Groundbreaking Personalized Melanoma Vaccine
The ministry approved two domestically developed medicines last year: Neooncovac, an mRNA-based vaccine for advanced melanoma, and Oncopept, a peptide therapy targeting aggressive colorectal cancers. Both began pilot human trials in 2025.
On Tuesday, Neooncovac was given to its first clinical recipient, a 60-year-old man with stage three skin cancer, according to Aleksandr Ginzburg, scientific director at the Gamaleya Research Institute of Epidemiology and Microbiology, which co-developed the vaccine.
“So far, he is doing well; there have been no adverse reactions to the drug,” Ginzburg told Russian media. “He is 60 years old and has stage three melanoma with metastasis. The vaccine specifically helps fight metastases.”
Researchers created the tailored vaccine by analyzing genomic samples from the patient’s tumor and healthy tissue, allowing the immune system to be trained to recognize and attack cancer cells.
“This is a fundamentally different approach – not simply treating the disease, but ‘training’ the immune system to recognize and destroy precisely those cells that pose a threat,” said Andrey Kaprin, head of the National Medical Research Center of Radiology at the Health Ministry.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
